Regeneron beats quarterly results estimates on strong Dupixent demand [Yahoo! Finance]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: Yahoo! Finance
for its ?eczema drug, Dupixent, and cancer drug, Libtayo, offsetting competitive pressures faced ?by eye drug Eylea. The company has been relying on Dupixent, which it co-develops with French drugmaker ?Sanofi, to offset pressure in its eye-drug business, where its blockbuster drug Eylea has faced competition from cheaper versions and rival treatments such as Roche's Vabysmo. Regeneron is trying to switch more patients to Eylea HD, the higher-dose version of ?the drug. Quarterly sales for Dupixent - ?the highest prescribed biologic by dermatologists and pulmonologists in the U.S. - recorded by Sanofi rose 33% to $4.88 billion, above analysts' ?estimates of $4.59 billion, according to LSEG data. Total Eylea sales, including the high dose, for the quarter fell 10% to $941 million. Eylea HD sales rose 52% to $468 ?million. Last year, ?the U.S. Food and Drug Administration declined ?to approve a pre-filled syringe ?version of Eylea HD due to issues at contract manufacturer, Cata
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of Sanofi [Yahoo! Finance]Yahoo! Finance
- Altuviiio (Swedish Orphan Biovitrum) Market Research Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2020-2025, 2025-2030F, 2035F [Yahoo! Finance]Yahoo! Finance
- Press Release: Annual General Meeting of April 29, 2026 - Belén Garijo appointed as Director and Chief Executive Officer of SanofiGlobeNewswire
- Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength [Seeking Alpha]Seeking Alpha
- Regeneron beats first quarter estimates on Dupixent strength [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 4/29/26 - Form 6-K
- 4/27/26 - Form 6-K
- 4/23/26 - Form 6-K
- SNY's page on the SEC website